Annual report pursuant to Section 13 and 15(d)

Nature of Business and Basis of Presentation

v2.4.0.8
Nature of Business and Basis of Presentation
 12 Months Ended
Dec. 31, 2013
Accounting Policies [Abstract]  
Nature of Business and Basis of Presentation

1. NATURE OF BUSINESS AND BASIS OF PRESENTATION

OncoGenex Pharmaceuticals, Inc. (referred to as “OncoGenex,” “we,” “us,” or “our”) is committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. We were incorporated in the state of Delaware and are headquartered in Bothell, Washington and have a subsidiary in Vancouver, British Columbia.

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States. The consolidated financial statements include the accounts of OncoGenex Pharmaceuticals, Inc. and its wholly owned subsidiary OncoGenex Technologies, Inc.

Liquidity

We have historically experienced recurring losses from operations that have generated an accumulated deficit of $133.7 million through December 31, 2013. At December 31, 2013, we had cash, cash equivalents and short-term investments of $39.2million.